- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07614776
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Amgen Call Center
- Telefonnummer: 866-572-6436
- E-post: medinfo@amgen.com
Studieorter
-
-
California
-
Fullerton, California, Förenta staterna, 92835-3432
- Rekrytering
- Retina Consultants of Orange County
-
Long Beach, California, Förenta staterna, 90607
- Rekrytering
- South Coast Retina Center - RCA
-
Modesto, California, Förenta staterna, 95356
- Rekrytering
- Retinal Consultants Medical Group, Inc - Modesto (RCA)
-
Pasadena, California, Förenta staterna, 91107
- Rekrytering
- California Eye Specialists Medical Group, Inc
-
Sacramento, California, Förenta staterna, 95825
- Rekrytering
- Retinal Consultants Medical Group, Inc - Sacramento - Parkcenter Drive (RCA)
-
Santa Barbara, California, Förenta staterna, 93103
- Rekrytering
- California Retina Consultants
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80909-1183
- Rekrytering
- Retina Consultants of Southern Colorado (Colorado Springs)- RCA
-
Colorado Springs, Colorado, Förenta staterna, 80909
- Rekrytering
- Retina Consultants of Southern Colorado (Pueblo)- RCA
-
Lakewood, Colorado, Förenta staterna, 80228
- Rekrytering
- Colorado Retina Associates (RCA)
-
-
Connecticut
-
Waterford, Connecticut, Förenta staterna, 06385
- Rekrytering
- Retina Group of New England
-
-
Florida
-
Miami, Florida, Förenta staterna, 33143
- Rekrytering
- Medeye Associates - Research
-
Naples, Florida, Förenta staterna, 34103-4457
- Rekrytering
- Retina Consultants of Southwest Florida - Naples
-
Pensacola, Florida, Förenta staterna, 32503
- Rekrytering
- Advanced Research, LLC
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60452
- Rekrytering
- University Retina and Macula Associates, PC
-
Elmhurst, Illinois, Förenta staterna, 60126
- Rekrytering
- Retina Associates
-
-
Indiana
-
Carmel, Indiana, Förenta staterna, 46032
- Rekrytering
- Associated Vitreoretinal and Uveitis Consultants
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21209
- Rekrytering
- The Retina Care Center- Baltimore (PRISM Vision Group)
-
Hagerstown, Maryland, Förenta staterna, 21740-5846
- Rekrytering
- Mid Atlantic Retina Specialists
-
Towson, Maryland, Förenta staterna, 21204-6833
- Rekrytering
- Retina Specialists
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Ophthalmic Consultants of Boston
-
-
Minnesota
-
Edina, Minnesota, Förenta staterna, 55435
- Rekrytering
- Retina Consultants of Minnesota (RCM) - St. Louis Park
-
-
Mississippi
-
Madison, Mississippi, Förenta staterna, 39110
- Rekrytering
- Mississippi Retina Assoc
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63128
- Rekrytering
- The Retina Institute, Research Retina Institute (RCA)
-
-
New Jersey
-
Bloomfield, New Jersey, Förenta staterna, 07003
- Rekrytering
- Envision Ocular, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87109
- Rekrytering
- Vision Research Center Eye Associates of New Mexico
-
-
New York
-
Liverpool, New York, Förenta staterna, 13088
- Rekrytering
- Retina Vitreous Surgeons of CNY, PC
-
Oceanside, New York, Förenta staterna, 11572
- Rekrytering
- Ophthalmic Consultants of Long Island - Research
-
Scarsdale, New York, Förenta staterna, 10583-5032
- Rekrytering
- Long Island Vitreoretinal Consultants(RCA Network)
-
-
North Carolina
-
Raleigh, North Carolina, Förenta staterna, 27607-7514
- Rekrytering
- North Carolina Retina Associates
-
Wake Forest, North Carolina, Förenta staterna, 27587
- Rekrytering
- NC Retina Associates- RCA
-
-
Ohio
-
Dublin, Ohio, Förenta staterna, 43016
- Rekrytering
- Midwest Retina - Main Office
-
-
Pennsylvania
-
Kingston, Pennsylvania, Förenta staterna, 18704-4801
- Rekrytering
- Eye Care Specialists - Kingston
-
-
South Carolina
-
Beaufort, South Carolina, Förenta staterna, 29902
- Rekrytering
- Retina Consultants of South Carolina, Charleston Neuroscience institute - Blufffon (RCA)
-
Charleston, South Carolina, Förenta staterna, 29414-5896
- Rekrytering
- Charleston Neuroscience Institute
-
Columbia, South Carolina, Förenta staterna, 29169
- Rekrytering
- Palmetto Retina Center - Main (RCA)
-
Ladson, South Carolina, Förenta staterna, 29456
- Rekrytering
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Ladson (RCA)
-
Mt. Pleasant, South Carolina, Förenta staterna, 29464
- Rekrytering
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Mount Pleasant (RCA)
-
West Columbia, South Carolina, Förenta staterna, 29169
- Rekrytering
- Palmetto Retina Center, Florence (RCA)
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Tennessee Retina PC
-
-
Texas
-
Arlington, Texas, Förenta staterna, 76012
- Rekrytering
- Texas Retina Associates (TRA) - Arlington
-
Austin, Texas, Förenta staterna, 78705
- Rekrytering
- Austin Retina Associates
-
Austin, Texas, Förenta staterna, 78705
- Rekrytering
- Austin Retina Associates - Ophthalmology/Retina
-
Bellaire, Texas, Förenta staterna, 77401
- Rekrytering
- Retina Consultants of Texas - Bellaire
-
Dallas, Texas, Förenta staterna, 75231
- Rekrytering
- Texas Retina Associates (TRA) - Dallas Main
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- Texas Retina Associates - Fort Worth
-
Houston, Texas, Förenta staterna, 77401
- Rekrytering
- Retina Consultants of Texas - Katy Retina Center
-
Katy, Texas, Förenta staterna, 77494
- Rekrytering
- Retina Consultants of Texas - The Woodlands
-
San Antonio, Texas, Förenta staterna, 78240
- Rekrytering
- Retinal Consultants of Texas- San Antonio
-
Schertz, Texas, Förenta staterna, 78154
- Rekrytering
- Retina Consultants of Texas - Schertz
-
Willow Park, Texas, Förenta staterna, 76087
- Rekrytering
- Strategic Clinical Research Group, LLC
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84107
- Rekrytering
- Retina Associates of Utah - Retina Specialist
-
-
Virginia
-
Falls Church, Virginia, Förenta staterna, 22042-2349
- Rekrytering
- Emerson Clinical Research- Virginia Retina Specialists
-
-
Washington
-
Bellevue, Washington, Förenta staterna, 98004-3779
- Rekrytering
- Vitreoretinal Associates of Washington
-
Silverdale, Washington, Förenta staterna, 98383
- Rekrytering
- Retina Center NW PLLC
-
Spokane, Washington, Förenta staterna, 99204-2509
- Rekrytering
- Spokane Eye Clinic (OCT and optical exam
-
-
-
-
-
Fukushima, Japan, 9601295
- Rekrytering
- Fukushima Medical University Hospital - Ophthalmology
-
Tokyo, Japan, 101-8309
- Rekrytering
- Nihon University Hospital - Ophthalmology
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 460-0008
- Rekrytering
- SUGITA EYE HOSPITAL - Ophthalmology
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 812-0011
- Rekrytering
- Hayashi Eye Hospital
-
-
Hyōgo
-
Amagasaki, Hyōgo, Japan, 660-8550
- Rekrytering
- Hyogo Prefectural Amagasaki General Medical Center - Ophthalmology
-
-
Osaka
-
Tennoji-Ku, Osaka, Japan, 543-0001
- Rekrytering
- University of the Ryukyus Hospital - Ophthalmology
-
-
Tokyo
-
Meguro-ku, Tokyo, Japan, 152-8902
- Rekrytering
- Tokyo Medical Center - Ophthalmology
-
Sendai, Tokyo, Japan, 984-8560
- Rekrytering
- Tokyo Medical University Hachioji Medical Center - Ophthalmology
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Rekrytering
- Yamaguchi University Hospital
-
Ube, Yamaguchi, Japan, 7558505
- Rekrytering
- Tokushima University Hospital - Ophthalmology
-
-
-
-
-
Riga, Lettland, 1002
- Rekrytering
- P.Stradina Clinical University Hospital - Ophthalmology
-
Riga, Lettland, LV-1002
- Rekrytering
- Riga East University Hospital - Department of Ophthalmology, Clinical Center "Bikernieki"
-
-
Riga
-
Riga, Riga, Lettland, LV-1009
- Rekrytering
- Latvian American Eye Center
-
-
-
-
Kaunas County
-
Kaunas, Kaunas County, Litauen, 50009
- Rekrytering
- Lietuvos Sveikatos Mokslu Universitetas (LSMU) - Kauno Klinikos - ophthalmology
-
-
-
-
-
Bytom, Polen, 41-902
- Rekrytering
- Caminomed Sp. z o.o.
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-631
- Rekrytering
- OFTALMIKA Sp. z o. o.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-411
- Rekrytering
- COMO Centrum Okulistyki Sp. z o.o.,
-
-
Lódzkie
-
Lodz, Lódzkie, Polen, 90-302
- Rekrytering
- Santa Familia PTG Lodz
-
-
Masovian Voivodeship
-
Krakow, Masovian Voivodeship, Polen, 30-363
- Rekrytering
- Szpital sw. Rozy Sp. z o.o.
-
-
Pomeranian Voivodeship
-
Warszawa, Pomeranian Voivodeship, Polen, 01-258
- Rekrytering
- Warszawski Szpital Okulistyczny
-
-
Warmian-Masurian Voivodeship
-
Olsztyn, Warmian-Masurian Voivodeship, Polen, 10-424
- Rekrytering
- Centrum Diagnostyki i Mikrochirurgii Oka-Lens Sp. z o.o.
-
-
-
-
Bratislava Region
-
Bratislava, Bratislava Region, Slovakien, 851 07
- Rekrytering
- Univerzitna nemocnica Bratislava - Ocna klinika SZU a UNB
-
Bratislava, Bratislava Region, Slovakien, 81108
- Rekrytering
- Univerzitna nemocnica - Nemocnica svateho Michala, a.s. - Ocna ambulancia
-
Bratislava, Bratislava Region, Slovakien, 821 03
- Rekrytering
- CMO Bratislava
-
Bratislava, Bratislava Region, Slovakien, 826 06
- Rekrytering
- Univerzitna nemocnica Bratislava - Klin. oftalmologie LFUK a UNB
-
Bratislava, Bratislava Region, Slovakien, 851 07
- Rekrytering
- Oftalmologicke centrum ProCare Betliarska
-
-
Košice Region
-
Trebišov, Košice Region, Slovakien, 075 01
- Rekrytering
- NsP Trebisov, a.s. - Ocne oddelenie
-
-
Nitra Region
-
Nitra, Nitra Region, Slovakien, 950 01
- Rekrytering
- Fakultna Nemocnica Nitra - Ocna Klinika
-
-
Trenčín Region
-
Banska Bystrica, Trenčín Region, Slovakien, 975 17
- Rekrytering
- FNsP F.D.R. Banska Bystrica - II. Ocna klinika SZU
-
Trenčín, Trenčín Region, Slovakien, 911 71
- Rekrytering
- Fakultna nemocnica Trencin - Ocna klinika
-
-
Žilina Region
-
Žilina, Žilina Region, Slovakien, 012 07
- Rekrytering
- Fakultna nemocnica s poliklinikou Zilina - Ocne oddelenie
-
-
-
-
-
Madrid, Spanien, 28041
- Rekrytering
- Hospital Universitario 12 de Octubre - Oftalmología
-
-
Barcelona
-
San Cugat Del Valles, Barcelona, Spanien, 08190
- Rekrytering
- Hospital Universitari General de Catalunya
-
-
Catalonia
-
Barcelona, Catalonia, Spanien, 8021
- Rekrytering
- Centro de Oftalmologia Barraquer (Barraquer Ophthalmology Centre)
-
-
Navarre
-
Navarra, Navarre, Spanien, 31008
- Rekrytering
- Clinica Universidad de Navarra - Oftalmología
-
-
Sevilla
-
Santiago de Compostela, Sevilla, Spanien, 15706
- Rekrytering
- Hospital Provincial De Conxo - Oftalmología
-
-
-
-
-
Prague, Tjeckien, 100 34
- Rekrytering
- FN Kralovske Vinohrady - Oftalmologicka klinika
-
-
Hradec Králové Region
-
Náchod, Hradec Králové Region, Tjeckien, 547 01
- Rekrytering
- Visus, spol. s r.o. - Nachod
-
-
Ostrava-město
-
Ostrava - Poruba, Ostrava-město, Tjeckien, 708 52
- Rekrytering
- Fakultni nemocnice Ostrava - Ocni klinika
-
-
Prague
-
Prague, Prague, Tjeckien, 150 00
- Rekrytering
- AXON clinical
-
Prague, Prague, Tjeckien, 128 08
- Rekrytering
- Vseobecna fakultni nemocnice v Praze - Ocni klinika
-
-
Stredoceský Kraj
-
Mladá Boleslav, Stredoceský Kraj, Tjeckien, 293 01
- Rekrytering
- Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho kraje - Klaudianova nemocnice
-
-
-
-
-
Budapest, Ungern, H-1062
- Rekrytering
- Eszak-pesti Centrumkorhaz - Honvedkorhaz
-
-
Baranya Varmegye
-
Dombóvár, Baranya Varmegye, Ungern, 7621
- Rekrytering
- Ganglion Orvosi Kozpont - Nozologen Kft - Szemeszet
-
-
Csongrad-Csanad Varmegye
-
Szeged, Csongrad-Csanad Varmegye, Ungern, 6720
- Rekrytering
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szemeszeti Klinika
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungern, 4032
- Rekrytering
- Debreceni Egyetem OEC - Ophthalmology
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Men or women ≥ 50 years old, capable of giving signed informed consent
- Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)
- Total area of CNV (including both classic and occult components) > 50% of the total lesion area in the SE
- The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE
- Presence of intra and/or subretinal fluid affecting the central subfield of the SE as identified by SD-OCT attributable to active CNV. The central subfield is defined as a circle with a diameter of 1 mm, centered on the fovea
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply at either screening or baseline, unless otherwise indicated per protocol:
- Total lesion size > 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye
- Scar, fibrosis, or atrophy involving the central subfield in the study eye
- Scar or fibrosis involving > 50% of the total lesion in the study eye
- Presence of retinal pigment epithelium tears or rips involving the macula in the study eye
- History of any vitreous hemorrhage ≤ 4 weeks (28 days) before randomization in the study
- Presence of other causes of CNV, including pathologic myopia (spherical equivalent ≥ 8 diopters negative or axial length ≥ 25 mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study
- Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication) in the study eye
- History or clinical evidence of DR, DME, idiopathic autoimmune uveitis, or any other vascular disease affecting the retina, other than nAMD in either eye
- Evidence of active extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening or randomization
- Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg). Blood pressure needs to be stable for at least 12 weeks (84 days) prior to screening
- Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti VEGF or anti-VEGF/anti-angiopoietin agent) in the SE, or surgery for nAMD in the SE, except dietary supplements or vitamins
- History or evidence of any other clinically significant disorder, condition, disease or clinical laboratory abnormality that, in the opinion of the investigator or study medical monitor, if consulted, would pose a risk to participant safety or interfere with the study evaluation or results interpretation
- Other protocol-specified exclusion criteria
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ABP 938 8 mg
Participants will receive intravitreal ABP 938 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with Dose Regimen Adjustment (DRA) decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection |
|
Aktiv komparator: Aflibercept (US) 8 mg
Participants will receive intravitreal Aflibercept (US) 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with DRA decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
Tidsram: Baseline and Week 12
|
Baseline and Week 12
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Percentage of Participants With Absence of Intraretinal Fluid (IRF) and Subretinal Fluid (SRF) in the Center Subfield, as Assessed by Spectral-Domain Optical Coherence Tomography (SD-OCT)
Tidsram: Week 16
|
Week 16
|
|
Change from Baseline in BCVA as measured by ETDRS letter score
Tidsram: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 24
Tidsram: Baseline to Week 24
|
Baseline to Week 24
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 48
Tidsram: Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Choroidal Neovascularization (CNV) Area Size as Measured by Fluorescein Angiography (FA)
Tidsram: Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Central Subfield Thickness (CST) as Measured by SD-OCT
Tidsram: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
Tidsram: Week 16 and Week 20
|
Week 16 and Week 20
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
Tidsram: Week 48
|
Week 48
|
|
Number of Participants Who Experienced Ocular Treatment-Emergent Adverse Events (TEAEs)
Tidsram: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Non-Ocular TEAEs
Tidsram: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Events of Interest (EOI)
Tidsram: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Serious Adverse Events (TESAEs)
Tidsram: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Developed Binding Antidrug Antibodies (ADAs)
Tidsram: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Free serum concentrations of ABP 938 8 mg
Tidsram: Week 16, week 24 and 48 (End of Study)
|
Week 16, week 24 and 48 (End of Study)
|
|
Free serum concentrations of Aflibercept (US) 8 mg
Tidsram: Week 16, week 24, and 48 (End of Study)
|
Week 16, week 24, and 48 (End of Study)
|
|
Pharmacokinetic (PK) parameters of ABP 938 8mg derived from concentration - time profiles following the first dose in a PK substudy
Tidsram: From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
|
Pharmacokinetic parameters of Aflibercept (US) 8 mg derived from concentration - time profiles following the first dose in a PK substudy
Tidsram: From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: MD, Amgen
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 20250115
- 2025-523500-72-00 (Ctis)
- 2025 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Tidsram för IPD-delning
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Kriterier för IPD Sharing Access
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .